134 related articles for article (PubMed ID: 37017934)
1. The frequency of fatty liver in patients with alopecia areata: A case-control study.
Tehranchinia Z; Abdollahimajd F; Haghighatkhah H; Talebi A; Yarahmadi A; Zoghi G
J Cosmet Dermatol; 2023 Sep; 22(9):2579-2583. PubMed ID: 37017934
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma in alopecia areata.
Arca E; Muşabak U; Akar A; Erbil AH; Taştan HB
Eur J Dermatol; 2004; 14(1):33-6. PubMed ID: 14965793
[TBL] [Abstract][Full Text] [Related]
3. Severe subtype of alopecia areata is highly associated with thyroid autoimmunity.
Bin Saif GA
Saudi Med J; 2016 Jun; 37(6):656-61. PubMed ID: 27279512
[TBL] [Abstract][Full Text] [Related]
4. Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population.
Mostaghimi A; Gao W; Ray M; Bartolome L; Wang T; Carley C; Done N; Swallow E
JAMA Dermatol; 2023 Apr; 159(4):411-418. PubMed ID: 36857069
[TBL] [Abstract][Full Text] [Related]
5. Demographic and Clinical Features of 1,641 Patients with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Single-Center Retrospective Study.
Uzuncakmak TK; Engin B; Serdaroglu S; Tuzun Y
Skin Appendage Disord; 2021 Jan; 7(1):8-12. PubMed ID: 33614711
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome in patients with Alopecia Areata: A case-control study.
Abdollahimajd F; Niknezhad N; Bahreini N; Younespour S; Namazi N
Dermatol Ther; 2021 Jul; 34(4):e14979. PubMed ID: 33991033
[TBL] [Abstract][Full Text] [Related]
7. All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States.
Mostaghimi A; Gandhi K; Done N; Ray M; Gao W; Carley C; Wang T; Swallow E; Sikirica V
J Manag Care Spec Pharm; 2022 Apr; 28(4):426-434. PubMed ID: 35332790
[No Abstract] [Full Text] [Related]
8. Alopecia Areata and Thyroid Dysfunction Association- A Study from Eastern Nepal.
Marahatta S; Agrawal S; Mehata KD
Kathmandu Univ Med J (KUMJ); 2018; 16(62):161-165. PubMed ID: 30636758
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and immunological studies on erythrocytes superoxide dismutase modified by nitric oxide in patients with alopecia areata: Implications in alopecia patchy persistent and alopecia universalis.
Rasheed Z; Alzolibani AA; Al-Shobaili HA; Saif GB; Al Robaee AA
Immunol Lett; 2014 Jul; 160(1):50-57. PubMed ID: 24694751
[TBL] [Abstract][Full Text] [Related]
10. Association of Alopecia Areata With Attention-Deficit/Hyperactivity Disorder Stimulant Medication: A Case-Control Study.
Meaux TA; McMahon PM; Jones GN; Bush AE; Kennedy JJ; Poche GW
Ochsner J; 2021; 21(2):139-142. PubMed ID: 34239372
[No Abstract] [Full Text] [Related]
11. Serum levels of total immunoglobulin e in patients with alopecia areata: relationship with clinical type of the disease.
Kasumagić-Halilović E; Prohić A
Acta Dermatovenerol Croat; 2006; 14(3):149-52. PubMed ID: 17010262
[TBL] [Abstract][Full Text] [Related]
12. Estimation of CD3, CD4, and CD8 in Iraqi patients with alopecia areata and alopecia universalis.
Aldaffaie STH; Hussein TA; Muhieldden AAR
J Cosmet Dermatol; 2022 Mar; 21(3):1286-1291. PubMed ID: 34731524
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the Risk of Alopecia Areata Progressing to Alopecia Totalis and Alopecia Universalis: Biomarker Development with Bioinformatics Analysis and Machine Learning.
Zhang T; Nie Y
Dermatology; 2022; 238(2):386-396. PubMed ID: 34004600
[TBL] [Abstract][Full Text] [Related]
15. Experience with oral tofacitinib in severe alopecia areata with different clinical responses.
Dincer Rota D; Emeksiz MAC; Erdogan FG; Yildirim D
J Cosmet Dermatol; 2021 Sep; 20(9):3026-3033. PubMed ID: 33533091
[TBL] [Abstract][Full Text] [Related]
16. The genetic basis of alopecia areata: HLA associations with patchy alopecia areata versus alopecia totalis and alopecia universalis.
Colombe BW; Lou CD; Price VH
J Investig Dermatol Symp Proc; 1999 Dec; 4(3):216-9. PubMed ID: 10674369
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of interferon-gamma (IFN-g) in patients with alopecia areata: correlation with clinical type and duration of the disease.
Kasumagic-Halilovic E; Prohic A; Karamehic J
Med Arh; 2010; 64(4):212-4. PubMed ID: 21246917
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
Dincer D; Tanacan E; Kose Ozkan C
J Cosmet Dermatol; 2021 Jun; 20(6):1807-1809. PubMed ID: 33098729
[TBL] [Abstract][Full Text] [Related]
19. Alopecia areata in Tunisia: epidemio-clinical aspects and comorbid conditions. A prospective study of 204 cases.
Arousse A; Boussofara L; Mokni S; Gammoudi R; Saidi W; Aounallah A; Belajouza C; Ghariani N; Denguezli M; Nouira R
Int J Dermatol; 2019 Jul; 58(7):811-815. PubMed ID: 30677128
[TBL] [Abstract][Full Text] [Related]
20. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata.
Akdogan N; Ersoy-Evans S; Doğan S; Atakan N
Dermatol Ther; 2019 Nov; 32(6):e13118. PubMed ID: 31621150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
